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ABSTRACT
Introduction: The global emergence of
pathogens of urinary-tract infections resistant
to ciprofloxacin or producing
extended-spectrum b-lactamases (ESBL) led us
to investigate the activity of older
antimicrobials such as cefprozil and cefixime
against a recent broad collection of urine
enterobacteria from 2012 and 2013.
Methods: Minimum inhibitory concentrations
and minimum bactericidal concentrations of
cefprozil, cefixime and ciprofloxacin were
determined against 293 Escherichia coli (40
ESBL producers), 54 Klebsiella pneumoniae (10
ESBL producers) and 53 Proteus mirabilis isolates.
Results: Cefprozil was more active than
ciprofloxacin against non-ESBL-producing
E. coli (93.7% vs 80.2%, p\0.0001); this was
not the case for cefixime (85.7% vs 80.2%, p:
0.125). Overall, cefprozil and cefixime inhibited
80–90% of ciprofloxacin-resistant isolates of all
studied species. However, they were active
against less than 20% of ESBL-producing
isolates.
Conclusion: Results suggest that cefprozil and
cefixime remain a good therapeutic alternative
against urine enterobacteria particularly in case
of ciprofloxacin-resistant pathogens. Their
activity against ESBL-producing pathogens is
limited.
Keywords: Cefprozil; Cefixime; Ciprofloxacin;
Escherichia coli; Urinary tract
INTRODUCTION
Urinary-tract infections (UTIs) are the second
most common cause of community-acquired
infections, with Escherichia coli being the most
common causative pathogen [1]. The great
majority of UTIs are easily manageable,
although some patients experience frequent
relapses [2]. Development of resistance is a
common characteristic of uropathogenic
microorganisms in the case of relapse [3].
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Cefprozil and cefixime are antimicrobials
introduced in the market more than two
decades ago. Cefprozil is a cephem
antimicrobial and cefixime is an orally
available third-generation cephalosporin. Since
enterobacteriaceae belong to their
antimicrobial spectrum, both these
antimicrobials are suggested for the
management of UTIs [4, 5]. For many years,
cefixime was considered an ideal alternative for
patients with acute pyelonephritis switching
from intravenous to oral therapy [5]. The
application of both these agents in the
therapeutic armamentarium against UTIs has
been abandoned over the years, whereas their
activity on urinary pathogens is not reported in
studies published over the last 5 years. The
emerging resistance of uropathogenic
enterobacteriaceae to commonly prescribed
antimicrobials [3] led us to conduct the
current study to investigate the activity of
cefprozil and cefixime against
enterobacteriaceae pathogens from patients
with community-acquired UTIs.
METHODS
This was a multicenter study that was
conducted during the period November 2012
until April 2013 among patients admitted for
urine culture into 10 different microbiology
laboratories in Greece. The study was approved
by the Ethics Committees of the Prefectures that
the labs refer to. Inclusion criteria were:
(a) written informed consent; (b) female
gender; (c) age C18 years; (d) at least two of
the following symptoms of acute cystitis, i.e.,
micturition, pain at urination and increased
frequency of urination; (e) one Gram-negative
isolate grown at quantity C105 cfu/ml from
midstream urine culture; (f) uncomplicated
cystitis; and (g) community-acquired UTI. The
episode of cystitis was considered
uncomplicated for non-pregnant
immunocompetent women without signs of
urinary obstruction on ultrasound, without
any abnormal findings on gynecologic
evaluation and without any urinary catheter.
Each patient could be enrolled once in the
study. For the UTI to be considered community
acquired, the patients should not have any
contact with health care systems for more than
90 days (i.e., no hospitalization, no residence in
long-term care facilities, no out-patient drug
infusions and no patients under chronic
hemodilution).
All isolates were transported onto slant agar
into the central lab of the 4th Department of
Internal Medicine at ATTIKON University
Hospital. After re-culture onto MacConkey agar
(BBL Becton–Dickinson, Cockeysville, MD,
USA), susceptibilities to ampicillin,
amoxicillin/clavulanate, cefoxitin, cefotaxime,
ceftazidime, cefepime, gentamycin, amikacin,
fosfomycin and trimethoprim/sulfamethoxazole
were determined by the disk diffusion method
using commercially available
antimicrobial-impregnated disks (Oxoid Ltd,
London, UK). Susceptibilities were interpreted
by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) breakpoints [6].
Extended-spectrum b-lactamases (ESBL)
production was tested with the double disk
approximation test [7].
All ESBL-producing isolates, all non-E. coli
isolates and almost half of the
non-ESBL-producing E. coli isolates were
selected for further study of susceptibilities to
cefprozil and cefixime. This was done by
selecting half of the non-ESBL-producing
E. coli coming from each laboratory. Minimum
inhibitory concentrations (MIC) to cefprozil,
cefixime and ciprofloxacin were determined by
a microdilution technique at a 0.1 ml final
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volume using one 5 9 105 cfu/ml log-phase
inoculum. Commercially available antibiotic
powders were purchased (Sigma Co, St. Louis,
USA). MIC was considered the lower
antimicrobial concentration inhibiting visible
bacterial growth after 18 h of incubation at
35 C. The EUCAST MIC susceptibility
breakpoints were used [6]. Minimum
bactericidal concentrations (MBC) were
determined after plating the content of clear
wells onto MacConkey agar performing three
times 1:10 serial dilutions. MBC was considered
as the lowest concentration which resulted in
the killing of 99.9% of the plated inoculum.
American Tissue Cell Collection isolate E. coli
25,922 was used as a reference strain.
MIC50 and MBC50 were determined as the
MIC and MBC respective values that inhibited/
killed 50% of isolates; MIC90 and MCB90 were
determined as the respective values inhibiting/
killing 90% of isolates. Susceptibilities were
compared by the Fischer exact test (SPSS
Statistics version 22.0, IBM, NY, USA). Any
value of p below 0.05 was considered
statistically significant.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study.
RESULTS
A total of 747 isolates were collected belonging
to the species of E. coli, Klebsiella pneumoniae
and Proteus mirabilis (Fig. 1). Overall prevalence
of ESBL production was 6.7%. E. coli was the
most common pathogen isolated from 85.7% of
patients. Among E. coli isolates, 93.8% were
non-ESBL producers and 6.2% were ESBL
producers. Among K. pneumoniae isolates,
81.8% were non-ESBL producers and 18.2%
were ESBL producers. None of the P. mirabilis
isolates were ESBL producers.
Against non-ESBL-producing E. coli, cefprozil
was more active than ciprofloxacin (93.7% vs
80.2% of isolates inhibited, p\0.0001). This
was not the case for cefixime (85.7% vs 80.2% of
isolates inhibited, p 0.125) (Table 1).
Although the activity of cefprozil and
cefixime was limited against ESBL-producing
isolates, they were active against isolates
resistant to ciprofloxacin (Table 2).
DISCUSSION
Current results suggest that in an era of
emerging antimicrobial resistance, cefprozil
and cefixime retain good activity against
enterobacteria from patients with
community-acquired UTI. However, both
antimicrobials are not active against isolates
that produce ESBL. Both tested drugs are
available for oral administration. Cefixime was
studied instead of other oral third-generation
Fig. 1 Flowchart of the selection of isolates for the study.
ESBL extended-spectrum b-lactamase
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Table 1 Susceptibility patterns of 400 urinary pathogens to cefprozil, ceﬁxime and ciproﬂoxacin in relation to their
resistance phenotype
MIC (lg/ml) MBC (lg/ml)







2 16 93.7 B0.125 to
[512
2 16 93.7






0.50 2 85.7 B0.125 to 512 0.50 2 84.2
ESBL (?) (n = 40) B0.125 to
[512




B0.015 to[32 0.03 [32 80.2 B0.015 to 64 0.03 [64 78.7
ESBL (?) (n = 40) B0.015 to[32 8 [32 37.5 B0.015 to 256 [64 [64 27.5
K. pneumoniae
Cefprozil (16)a
ESBL (-) (n = 44) B0.125 to
[512
1 16 93.2 B0.125 to
[512
1 16 90.9
ESBL (?) (n = 10) 1 to[512 [512 [512 10.0 4 to 512 [512 [512 10.0
Ceﬁxime (1)a
ESBL (-) (n = 44) B0.125 to
[512
0.25 1 95.5 B0.125 to 512 0.25 1 95.5
ESBL (?) (n = 10) B0.125 to
[512
[512 [512 10.0 B0.125 to 512 [512 [512 10.0
Ciproﬂoxacin (1)a
ESBL (-) (n = 44) B0.015 to[32 0.03 [32 77.3 B0.015 to 64 0.03 [32 77.3
ESBL (?) (n = 10) B0.015 to[32 0.50 [32 50.0 B0.015 to 64 64 64 30.0
P. mirabilis
Cefprozil (16)a
ESBL (-) (n = 53) 0.50 to 128 2 16 90.6 0.50 to 128 4 32 88.7
Ceﬁxime (1)a
ESBL (-) (n = 53) B0.125 to 4 B0.125 1 100.0 B0.125 to 4 B0.125 1 100.0
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cephalosporins because it is the only drug of
this class still in the market both in Greece and
in many other European countries. The plasma
half-life of cefprozil is 1.3 h and its
bioavailability is 100%; it should be
administered at a 500-mg twice-daily oral dose
for 5–7 days for the treatment of UTIs. The
plasma half-life of cefprozil is 4 h and its
bioavailability is 50%; it should be
administered at a 400-mg once-daily oral dose
for 5 days for the treatment of UTIs [8].
Current guidelines suggest oral quinolones
as the first-line treatment for
community-acquired UTIs [9]. However,
resistance to quinolones has emerged and
mounts close to 20% as reported in a large
survey of 499 E. coli isolates from Germany [10].
This increase in resistance of E. coli urine
isolates to ciprofloxacin seems to be a
worldwide phenomenon [2]. A retrospective
analysis of the yearly susceptibility trends of
1107 community E. coli urine isolates in the
Adelaide and Meath Hospital, that is a national
tertiary reference center for urology in Ireland,
indicated resistance rate of 10.6%. This
amounts to 17.8% for hospital-acquired
isolates and to 28.6% for isolates coming from
patients hospitalized in urology departments
[2]. However, the resistance rates to
ciprofloxacin of 723 community-acquired
urine E. coli isolates from inpatients enrolled
in the SMART program of antimicrobial
surveillance in USA during the years
2009–2011 was 22.4%. This was 7.4% for the
167 community-acquired urine isolates of K.
pneumoniae [11]. The main driver for acquisition
of ciprofloxacin resistance in the community is
consumption of ciprofloxacin the last 3 months
associated with odds ratio 4.20 [3]. In our study,
cefprozil inhibited E. coli at a rate significantly
greater than ciprofloxacin; both cefprozil and
cefixime retained good activity against
ciprofloxacin-resistant isolates. As a
consequence, they remain a good therapeutic
alternative either for empirical treatment, in the
case of high suspicion for
ciprofloxacin-resistant pathogens, or when one
ciprofloxacin-resistant pathogen is isolated
from urine.
One huge emerging problem in the
management of community-acquired UTIs is
enterobacteria pathogens that are
b-lactam-resistant through the production of
ESBL. Current publications suggest that the
prevalence of these isolates ranges between 2
and 6% in E. coli and it is higher in K.
pneumoniae [10, 12, 13]. These rates are in
accordance with the 6.7% prevalence reported
in the present study. Female gender, recurrent
UTIs and presence of comorbidities are the most
common risk factors for the acquisition of these
isolates [12, 13]. Our findings suggest that both
cefprozil and cefixime have poor activity
against these isolates and that they cannot be
suggested for management. Their empirical use
should not be considered when there is
Table 1 continued
MIC (lg/ml) MBC (lg/ml)
Range MIC50 MIC90 % inhibited Range MBC50 MBC90 % killed
Ciproﬂoxacin (1)a
ESBL (-) (n = 53) B0.015 to[32 0.06 8 79.2 B0.015 to 64 0.06 8 77.4
ESBL extended-spectrum b-lactamase, MBC minimum bactericidal concentration, MIC minimum inhibitory concentration
a Susceptibility concentration breakpoint
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increased clinical suspicion for UTIs by
ESBL-producing pathogens.
The current study did not focus on
epidemiological information of patients with
UTIs caused by ESBL-producing isolates and
ciprofloxacin-resistant isolates. This is because a
previous large-scale epidemiological study in
Greece has clearly shown the impact of previous
antimicrobial consumption in the last 3 months
as a risk factor for the emergence of these
resistant isolates [3]. Major emphasis was given
on the use of cefprozil and cefixime as
alternative treatments for UTIs.
CONCLUSION
The results of the present study indicate that
cefprozil and cefixime retain good activity
against urine pathogens. According to our
findings, they can be empirically used for
management. Their use is particularly
encouraged in the following cases: (a) UTIs
with documented or high suspicion for
implication of ciprofloxacin-resistant
pathogens; and (b) UTIs by pathogens
cross-resistant to other antimicrobials provided
that they do not produce ESBL.
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